Twist Bioscience Q2 FY2025 Earnings Summary

Twist Bioscience reported strong results for the second quarter of fiscal year 2025, showing continued revenue growth and improving margins, while announcing a strategic spin-out.
Key Financial Highlights (Q2 FY2025 vs Q2 FY2024):
• Revenue: $92.8 million (up 23% from $75.3M)
o SynBio: $36.0M (up 21%)
o NGS: $51.1M (up 25%)
o Biopharma: $5.7M (up 21%)
• Gross margin: 49.6% (up from 41.0%)
• Net loss: $39.3M or $0.66 per share (improved from $45.5M or $0.79)
• Adjusted EBITDA: $(14.8)M (improved from $(26.8)M)
• Cash & investments: $257.1 million
Business Highlights:
• Spun out Atlas Data Storage, backed by major investors like ARCH Venture, Deerfield, Bezos Expeditions, and In-Q-Tel.
• Shipped to ~2,431 customers (up from ~2,253) and delivered ~227,000 genes (up from ~193,000).
• Partnered with Curio Genomics to enhance NGS offerings in agrigenomics.
• Launched high-throughput dual index adapter system.
FY2025 Guidance (unchanged revenue range, improved margins):
• Revenue: $372–$379 million (19–21% YoY growth)
o SynBio: $144–$147M
o NGS: $205–$209M
o Biopharma: ~$23M
• Gross margin: ~49.5% for FY25; >50% expected in Q4
• Adjusted EBITDA: $(48)M to $(53)M (narrowed from $(55)M–$(60)M)
• EBITDA breakeven targeted by end of FY2026